Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From AlphaCore Pharma
Deal Watch: Auxilium Accepts Endo Buyout Rather Than Completing Purchase Of QLT Shell
Actavis continues filling out its portfolio by acquiring Durata, but leaves room for other transformational deals. Impax moves strongly into generics and adds an FDA-licensed manufacturing site in buying three companies under the Tower Holdings umbrella.
Dunoyer Makes Leap To CFO As AZ’s BD Overhaul Continues
As AstraZeneca’s global product chief Marc Dunoyer moves on to the CFO job, he leaves a newly restructured, active, and decentralized dealmaking organization.
AZ Builds Cardiac Regeneration, Diabetes R&D At Swedish Research Hub
Diabetic nephropathy, pancreatic islet cell health as well as heart failure will feature in early-stage research conducted by AstraZeneca's cardiometabolic iMED based in Mölndal, Sweden - now one of three strategic R&D centers for the trimmed-down British drug maker.
AstraZeneca To Share FibroGen’s Anemia Compound With Astellas, But Will Hoard China For Itself
In FibroGen’s FG-4592, AstraZeneca sees a potential strong seller in China where the privately held biotech's other pharma partner, Astellas, doesn’t already own rights.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.